![]() The trial will now be reopened for screening, enrollment and dosing at multiple sites in the United States. The study was placed on clinical hold by the FDA based on its determination of insufficient information for dose escalation with the product. The study was for people with type 1 diabetes (T1D) with impaired hypoglycemic awareness and severe hypoglycaemia. VX-880 is a stem cell-derived, fully differentiated islet replacement therapy used in combination with standard immunosuppression to protect the implanted cells. ![]() Regulatory Update From Vertex: Vertex Pharmaceuticals ( VRTX Quick Quote VRTX - Free Report) announced that the FDA has lifted the clinical hold placed on the phase I/II study of experimental candidate VX-880. ![]() Recap of the Week’s Most Important Stories: Acquisitions and collaborations have also taken center stage in this space. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.The biotech sector has been in the spotlight in the past week with important pipeline and regulatory updates. MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to. Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |